



(51) International Patent Classification: Not classified

(21) International Application Number:  
PCT/EP2009/063503

(22) International Filing Date:  
15 October 2009 (15.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/106,231 17 October 2008 (17.10.2008) US  
61/106,260 17 October 2008 (17.10.2008) US  
12/578,934 14 October 2009 (14.10.2009) US

(71) Applicants (for all designated States except US):  
**JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). **mitsubishi TANABE PHARMA CORPORATION** [JP/JP]; 2-6-18, Kitahama Chuo-ku, Osaka 541-8505 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FILLIERS, Walter Ferdinand Maria** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BROECKX, Rudy Laurent Maria** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **NIESTE, Patrick Hubert J.** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **HATSUDA, Masanori** [JP/JP]; c/o MITSUBISHI TANABE PHARMA CORPORATION, 2-6-18, Kitahama Chuo-ku, Osaka 541-8505 (JP). **YOSHINAGA, Masahiko** [JP/JP]; c/o MITSUBISHI TANABE PHARMA CORPORATION, 2-6-18, Kitahama Chuo-ku, Osaka 541-8505 (JP). **YADA, Mitsuhiro** [JP/JP]; c/o MITSUBISHI TANABE PHARMA CORPORATION, 2-6-18, Kitahama Chuo-ku, Osaka 541-8505 (JP).

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

**Published:**

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(54) Title: PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT

(57) Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.



WO 2010/043682 A2